Results 91 to 100 of about 557 (132)
Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity. [PDF]
Diabetes TherVolčanšek Š +4 more
europepmc +1 more source
Lancet, The, 2023 BACKGROUND: Combining the GLP-1 receptor agonist semaglutide with the long-acting amylin analogue cagrilintide has weight-loss benefits; the impact on glycated haemoglobin (HbA1c) is unknown. This trial assessed the efficacy and safety of co-administered
Ildiko Lingvay, Juan Frias, Filip K Knop
exaly +11 more sources
Cagrilintide–Semaglutide in Adults with Overweight or Obesity
New England Journal of MedicineIn the REDEFINE 1 trial, Garvey and colleagues (Aug. 14 issue)1 report the efficacy of combination therapy with cagrilintide and semaglutide (known as CagriSema) in patients with overweight or obesity who did not have diabetes. The authors acknowledge the predominance of female participants as a limitation.
Hao, Chi, Hua, Yang, Youping, Deng
exaly +9 more sources
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
New England Journal of MedicineSemaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg has shown promising results in early-phase trials; the efficacy of the combination (known as CagriSema) on weight loss in persons with either overweight and coexisting conditions or obesity is unknown.In a phase 3a, 68-week ...
Niels Zeuthen
exaly +5 more sources
Development of Cagrilintide, a Long-Acting Amylin Analogue [PDF]
Journal of Medicinal Chemistry, 2021 A hallmark of the pancreatic hormone amylin is its high propensity toward the formation of amyloid fibrils, which makes it a challenging drug design effort. The amylin analogue pramlintide is commercially available for diabetes treatment as an adjunct to insulin therapy but requires three daily injections due to its short half-life.
Eva Johansson +2 more
exaly +3 more sources
Cagrilintide plus semaglutide for obesity management
Lancet, The, 2021 Cagrilintide is a novel long-acting amylin receptor agonist, which has shown a potent induction of weight loss. Interestingly, cagrilintide is a Dual Amylin and Calcitonin Receptor Agonist (DACRA) derived from an amylin backbone. Another class of long-acting DACRAs exists, namely the KBPs.
Sara Becerril, Gema Frühbeck
exaly +8 more sources
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial [PDF]
Lancet, The, 2021 BACKGROUND: Natural amylin is a pancreatic hormone that induces satiety. Cagrilintide is a long-acting amylin analogue under investigation for weight management.
Carel le Roux +2 more
exaly +2 more sources
Cagrilintide Combined with Semaglutide: a new Approach for Treatment of Obesity and type 2 Diabetes
Clinical Research and Clinical Trials, 2023 Cagrilintide is a long-acting amylin receptor agonist that lowers body weight and controls hyperglycemia through various actions. In a phase 2 trial of obese subjects, cagrilintide used in different subcutaneous doses once weekly was associated with a mean weight loss of 6-10.8% after 26 weeks, compared with 9.0% with the glucagon-like 1 receptor (GLP ...
Nasser Mikhail
exaly +2 more sources